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Loss of a tumor-suppressor gene function appears to play a critical role in the multistep process of
neoplastic transformation of Syrian hamster embyro (SHE) cells in vitro. Clonal variants of two inde-
pendent, preneoplastic cell lines havebeen isolatedthathaveeitherretained(termedsupB+) orlost(termed
supB W) the ability to suppress the tumorigenicity ofa highly malignant benzo[a]pyrene-transformed SHE
cell line (BP6T) in cell hybrids. We have pursued several approaches in an attempt to identify genes that
are responsible for tumor suppression in these cells. The only consistent differences detected in two-
dimensional gel analyses of supB+ and supB- cellular proteins were decreases in the levels of two high
molecular weight isoforms oftropomyosin in supB cells. Differential screening ofa supB+ cDNA library
for genes that are preferentially expressed in supB+ cells yielded cDNAclones forfourgenes, i.e., collagen
type II, collagentype IX, H19, andapreviouslyunidentifiedgene(clone5). Nuclearrun-onassayssuggested
that higher transcription rates were responsible for the increased steady-state levels of some of these
transcripts in supB+ cells. DNAsequence comparisons showed thattwocopies ofa 9 bpelement, previously
identified in each ofthe mouse H19 enhancers, were also present in the 5' flanking region ofthe rat type
II collagen gene. A transcription factor that controls expression of the collagen and H19 genes through
binding to this conserved motifwould be an attractive candidate for the supB+ gene or at least a mediator
of the supB+ phenotype.
Role of Tumor-Suppressor Genes in
Multistep Carcinogenesis
It is now well established that the carcinogenic pro-
cess requires the accumulation ofmultiple heritable al-
terations for the complete malignant transformation of
normal cells (1-3). It is also clear that the inactivation
of tumor-suppressor genes plays an important role in
the genesis of a wide variety of human tumors (3,4).
Strong evidence for this concept has been provided by
studies of the suppression oftumorigenicity in somatic
cellhybrids (5,6), geneticpredispositions to cancer(7,8),
and nonrandom chromosomal deletions or allelic losses
in specific chromosomal regions (9,10). A number of
these tumor-suppressor genes have recently been iso-
lated by molecular cloning techniques (11-15), and in
several cases tumor-suppressor activity has been dem-
onstrated in functional assays (16-18).
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We have previously demonstrated that the loss or
inactivation of a tumor-suppressor gene function is a
critical event during the neoplastic transformation of
carcinogen-treated or oncogene-transfected Syrian
hamster embryo cells in vitro (19,20). The conversion
of these normal cells to fully malignant tumor cells is
clearly a multistep process (Fig. 1). Rare cells in car-
cinogen-treated cultures escape cellular senescence and
form immortal (sen-) cell lines (21,22). These cell lines
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FIGURE 1. A pathway for neoplastic progression of Syrian hamster
embryo cells in vitro.WISEMAN ET AL.
are preneoplastic and require many population dou-
blings invitro priortobecominganchorageindependent
(SA+) or tumorigenic (tum+) when injected subcuta-
neously into nude mice. The tumorigenic phenotype is
strongly suppressed in cell hybrids formed between a
benzo[a]pyrene-induced tumorcell line (BP6T) and nor-
mal SHE cells or early passage preneoplastic lines. At
laterpassages, however, the abilityofpreneoplastic cell
populations to suppress tumorigenicity becomes het-
erogeneous (19). A series of variants that differ more
than 15- to 30-fold in their ability to suppress the tu-
morigenicity of BP6T cells (Table 1) have been sub-
cloned from two independent preneoplastic lines (DES4
and lOW) (23). These subclones are designated supB+
or supB- since BP6T cells represent only one ofat least
three different complementation groups for tumor sup-
pression of hamster sarcomas (24). Interestingly, the
supB- phenotype co-segregates with the ability to re-
versibly grow with high cloning efficiencies in soft agar
supplemented with tumor cell-conditioned media or a
combination of epidermal growth factor, insulin, and
platelet-derived growth factor (19,23).
Identification of Genes Preferentially
Expressed in Cells Retaining the
Ability to Suppress Tumorigenicity
To isolate candidates for the BP6T tumor-suppressor
gene function, we have used two approaches to identify
genes that are preferentially expressed in supB+ cells
relative to supB- cells. The feasibility of these ap-
proaches is enhanced by the fact that the supB+ and
supB- cell lines are very closely related, having been
subcloned from the same parental lines. In addition, we
have used supB+ and supB- variants derived from two
independentparentalcelllines, i.e., DES4and lOW(23);
this should increase the probability that the alterations
Table 1. Suppression of BP6T cell tumorigenicity by supB+ and
supB- clonal variants.
Tumor Tumor
Parental suppression Fold suppression
cellsa ratio' suppressionc phenotype
DES4 0.90 1.1 supB-
DES4 1.05 1.0 supB-
DES4 0.039 25 supB+
DES4 0.031 32 supB+
lOW 0.95 1.0 supB-
lOW 1.11 0.9 supB-
lOW 1.07 0.9 supB-
lOW 0.037 27 supB+
lOW 0.066 15 supB+
'DES4 (passage 60) and lOW (passage 17) cells were subeloned by
one oftwo methods, i.e., colonies growing in agar supplemented with
BP6T tumor cell-conditioned medium (conditionally transformed) or
colonies growing in normal medium on plastic tissue culture dishes.
bThe ratio ofhybrid colonies formed with BP6T cells that grow in
agar to total hybrid colonies forned on plastic.
cl/tumor suppression ratio. These data were modified from Koi et
al. (23) with permission.
we have detected are directly related to the supB+
phenotype rather than simply fortuitous events.
Initially, we examined the levels of more than 1000
[35S]methionine-labeled proteins from total cell lysates
ofthe supB+ and supB- subclones using the Quest sys-
tem (25) for quantitative two-dimensional gel electro-
phoresis. These studieswere performedin collaboration
with Michael Lambert and James Garrels (Cold Spring
Harbor Laboratory). Given the sensitivity of this type
ofanalysis, specific protein levels were very similar be-
tween the two cell types, as expected for these clonal
derivatives. The only consistent alterations that were
detectedbetweeneachofthesupB+ andsupB- celllines
were reductions of two high molecular weight tropo-
myosins in supB- cells (26). These tropomyosin iso-
forms were identified by comparisons with two-dimen-
sional gel patterns ofrat and human proteins as well as
by immunoprecipitation with tropomyosin-specific anti-
sera. Tropomyosin 1 and tropomyosin 2 levels were de-
creased 6-fold and 2-fold, respectively, in supB- cells
relative to supB+ cells. Analysis of silver-stained gels
revealed similar reductions in the steady-state levels of
these proteins in supB- cells. Likewise, comparable de-
creases in tropomyosin 1 mRNA were observed by
Northern analysis with a rat tropomyosin cDNA probe
in supB- cells.
Previous studies by several laboratories have re-
ported decreased expression of high molecular weight
tropomyosin isoforms in virally and chemically induced
tumorcells relative toimmortal precursorcells (27-30).
However, our observations are the first example of al-
tered tropomyosin expression in cellspriortoneoplastic
transformation. Stress fiber organization in supB+ and
supB- cells was also compared since tropomyosins are
cytoskeletal proteins that are thought to stabilize actin
microfilaments. Fluorescent microscopy ofcells stained
with rhodamine-phallodin demonstrated that the actin
stressfibers ofsupB+ cellswerehighlyorganized, while
supB- cells consistently exhibited a diffuse, disorgan-
ized actin staining pattern common in tumor cells (31;
J. Boyd, unpublished results). Studies using antisense
techniques are underway to address a possible role for
these cytoskeletal alterations in the supB+ phenotype.
The second approach (Fig. 2) that we have adopted
to identify genes that are preferentially expressed in
supB+ cells is the differential screening of cDNA li-
braries (31). A series of31 supB+ specific plaques were
isolated by screening a DES4supB+ cell lambda ZAP
cDNA library sequentially with 'P-labeled total cDNA
probes prepared from DES4supB- and DES4supB+
mRNA. For further analysis, cDNA inserts were ex-
cised from the lambda ZAP phage as pSK- phagemid.
These cDNA clones represented four different genes
based on Northern analyses and cross-hybridization
studies.
Northern analysiswithtwo ofthese cDNAsasprobes
revealed transcripts of5.1 kb and 4.5 kb, respectively,
that are abundant in supB+ cells but absent or barely
detectable in normal SHE cells, supB- cells, and BP6T
cells. DNAsequencingrevealedthatthese cDNAswere
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FIGURE 2. A cDNA library was constructed in lambda ZAP with
mRNA from the DES4supB+3 cell line. This library was sequen-
tially screened with cDNA probes prepared from DES4supB-3
and DES4supB+3 mRNA. Thirty-one plaques that hybridized
preferentially to the supB + were selected for further analysis.
the hamster homologs ofthe otl chains ofcollagen type
II and collagen type IX, which are normally expressed
in chondrocytes (37). This suggests that the parental
lOW and DES4 cell lines used in our studies are derived
from a chondrocyte precursor or a chondrocyte-com-
mitted cell type. These cells must represent a minor
subpopulation within primary SHE cell cultures since
expression of these chondrocyte-specific collagens was
barely detectable by Northern analysis of SHE cell
RNA. It will be interesting to determine whether or
not this cell type is a common target for carcinogen-
induced immortalization of SHE cells.
The third cDNA detects a2.4 kb transcript on North-
ern blots, which is expressed at high levels in SHE cells
and DES4supB+ lines but not in DES4supB- lines or
BP6T cells. However, the levels of this mRNA do not
consistently correlate with the supB+ phenotype in the
lOW subclones. DNA sequence analysis identified this
cDNA as the hamster homolog ofthe H19 gene. Tilgh-
man and co-workers (38) originally identified H19 by
differential cDNA screening as a gene that was ex-
pressed coordinately with ao-fetoprotein. This gene is
developmentally regulated with expression of ex-
tremely high levels in many tissues during mouse em-
bryogenesis, but its function remains unknown. Since
no significant openreadingframes are conserved among
the mouse, human, andhamsterhomologs, the H19 gene
may function at the RNA level (39).
Northern analysis with the remaining cDNA (clone
5) revealed a series of transcripts, with major species
of 2.5 kb and 3.0 kb as well as several less abundant,
larger mRNAs. These transcripts were observed in
each ofthe supB+ lines and normal SHE cells but were
undetectable in the supB- lines and BP6T cells. DNA
sequenceanalysis ofover2kbatthe3' endofthiscDNA
has failed to reveal any significant similarities with se-
quences currently in the GenBank or European Molec-
ular Biology Laboratory databases.
In an attempt to understand the basis for the coor-
dinate expression of these genes in supB+ and supB-
cells, nuclear run-on assays were performed forthe col-
lagen and H19 genes. These studies suggested that
higher transcription rates were responsible for the in-
creased steady-state levels of these transcripts in
supB+ cells. DNA sequence comparisons showed that
a 9 bp element, TGT(T/C)TGCAG, that was previously
identified in each ofthe mouse H19 enhancers was also
present twice in the 5' flanking region of the rat type
II collagen gene (36,40). Preliminary gel retardation
assays revealed the presence offactor(s) in nuclear ex-
tracts of supB+ cells that bound to an oligonucleotide
containing this conserved motif. Current studies using
cDNA expression vector libraries are directed at the
isolation of factors that bind to oligonucleotides con-
taining this sequence element.
Conclusions
In this review, we have described two approaches
that are directed toward the isolation ofthe supB+ tu-
mor-suppressorgene. Althoughtheidentityofthisgene
is still unknown, a series of genes whose expression is
coordinately regulated with the supB+ phenotype have
been identified. Iftechniques such as differential cDNA
screening and two-dimensional protein gel analysis are
to succeed, it is essential that the cells being compared
are as closelyrelated as possible. The supB+ and supB-
cells that we have studied appear to fulfill this criteria.
Furthermore, these techniques are based on the hy-
pothesis that the expression of the supB+ tumor-sup-
pressor gene will be absent or greatly decreased in
supB- cells. While this assumption is valid for several
tumor-suppressor genes that have previously been
cloned (11,12), genes like the P53 gene, which is func-
tionally inactivated by point mutations (41), would be
missed by these techniques.
The detection ofa tumor-suppressor gene product by
quantitative two-dimensional gel analysis is limited to
moderately abundant proteins that are clearly resolved
under the electrophoresis conditions employed. Like-
wise, isolation ofthe supB+ gene by differential cDNA
screening requires that this gene be expressed as a
relatively abundant transcript (> 0.05% of the total
mRNA) so that it is represented at a sufficient level in
the 32P-labeled probe toyield adetectable hybridization
signal (42). However, subtractive hybridization tech-
niques have been used to isolate considerably less abun-
dant transcripts (43,44), and they provide an attractive
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extension of the differential cDNA screening studies
described in this report. Therefore, our current efforts
are directed at the construction of a supB+ cDNA li-
brary after several rounds of subtraction with supB-
mRNA. Subtractive hybridization techniques using a
mammalian expression vector may also be useful as an
enrichment for supB+ cDNAs with the potential to sup-
press the tumorigenicity of BP6T cells. Such a sub-
tracted supB+ library could be used in gene transfer
assays likethose described byNodaand co-workers (16)
to screen for cDNAs with tumor-suppressing activity.
Of the genes identified whose expression is coordi-
nately regulated with a tumor-suppressor function for
BP6T cells, two (collagen type II and collagen IX) are
differentiation markers, and another (H19) is a devel-
opmentally regulated gene. The loss of expression of
these differentiation and developmental genes is con-
sistent with the suggestion by Stanbridge and others
(5,8) that tumor-suppressor genes may function by in-
ducing differentiation in vivo. Several studies have im-
plicated transcription factors in the control of differ-
entiation, e.g., MyoD in the myogenic differentiation
program (44). Since two copies of a 9 bp element,
TGT(T/C)TGCAG, are conserved between the mouse
H19 enhancers and the 5' untranslated region ofthe rat
type II collagen gene, we are currently investigating
the existence of a potential transcription factor that
binds this sequence and may control the coordinate
expression of these genes with the supB+ phenotype.
Such a transcription factor would be an attractive can-
didate as a mediator ofchondrocyte differentiation and
the supB+ phenotype, ifnot the supB+ gene itself. This
concept is especially intriguing in light of the recent
report (45) ofarole forthe retinoblastoma gene product
in transcriptional control of the c-fos promoter.
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